Information about the Company
Founded in 2012, Greenyn Biotechnology Co., Ltd. is a leading international dietary supplement company. Listed on the OTD in 2023, it also serves as an exclusive distributor for foreign dietary supplement ingredients and offers ODM product development and design.
Greenyn Biotechnology focuses on developing dietary supplements with distinct Taiwanese characteristics and international competitiveness. It provides professional one-stop services, creating efficient and uniquely differentiated dietary supplement products for clients.
Greenyn Biotechnology has a proven track record of delivering thousands of customized products to hundreds of domestic and international clients over decades. Their dedicated dietitians and marketing teams collaborate with partners to ensure successful product launches.
Greenyn has obtained multiple international food quality system certifications such as FSSC 22000, ISO 22000, HACCP, HALAL, ISO/IEC 17025, GMP, and other laboratory certifications. The core values of the company coil around R&D, innovation, accurate optimization, and integrated marketing.
Greenyn leverages over two decades of marketing expertise, a strong R&D team, and collaborations with industry and academic experts to swiftly commercialize innovative products. Their commitment to excellence is reflected in their products, which feature international certifications, proven efficacy, global patents, superior specifications, and competitive pricing.
Corporate Culture & Company Activities
Greenyn Biotechnology, is recognized as a certified Healthy Workplace by the Ministry of Health and Welfare. It was also acknowledged as a "CHR Healthy Corporate Citizen" by CommonHealth Magazine in 2023.
The company values the health, safety, and dignity of all employees, while also emphasizing employee welfare and talent development. Greenyn goes beyond legal requirements, offering comprehensive health check-ups, cancer screenings and extended insurance coverage covering cancer, medical bills, and accident insurance, all fully paid by the company.
Greenyn also hosts health seminars, provides nutritionist consultations, and strives to enhance the physical, mental, and spiritual well-being of its employees. Additionally, it fosters a friendly workplace with employee activities, family days, employee clubs, and generous travel subsidies. The company also invests 1-3% of its annual revenue in education and training, encouraging employees to further their education and develop their careers.
Greenyn believes in aligning sustainable business practices with global trends to positively impact the environment, society, and the economy, achieving ESG goals. Since 2022, Greenyn has used the FSB's TCFD framework to assess and manage the impact of climate change, identifying related risks and opportunities. Greenyn also supports rural education, underprivileged groups, and community care programs for the elderly, regularly hosting health seminars to strengthen its commitment to social responsibility.
Founded in 2012, Greenyn Biotechnology Co., Ltd. is a leading international dietary supplement company. Listed on the OTD in 2023, it also serves as an exclusive distributor for foreign dietary supplement ingredients and offers ODM product development and design.
Greenyn Biotechnology focuses on developing dietary supplements with distinct Taiwanese characteristics and international competitiveness. It provides professional one-stop services, creating efficient and uniquely differentiated dietary supplement products for clients.
Greenyn Biotechnology has a proven track record of delivering thousands of customized products to hundreds of domestic and international clients over decades. Their dedicated dietitians and marketing teams collaborate with partners to ensure successful product launches.
Greenyn has obtained multiple international food quality system certifications such as FSSC 22000, ISO 22000, HACCP, HALAL, ISO/IEC 17025, GMP, and other laboratory certifications. The core values of the company coil around R&D, innovation, accurate optimization, and integrated marketing.
Greenyn leverages over two decades of marketing expertise, a strong R&D team, and collaborations with industry and academic experts to swiftly commercialize innovative products. Their commitment to excellence is reflected in their products, which feature international certifications, proven efficacy, global patents, superior specifications, and competitive pricing.
Corporate Culture & Company Activities
Greenyn Biotechnology, is recognized as a certified Healthy Workplace by the Ministry of Health and Welfare. It was also acknowledged as a "CHR Healthy Corporate Citizen" by CommonHealth Magazine in 2023.
The company values the health, safety, and dignity of all employees, while also emphasizing employee welfare and talent development. Greenyn goes beyond legal requirements, offering comprehensive health check-ups, cancer screenings and extended insurance coverage covering cancer, medical bills, and accident insurance, all fully paid by the company.
Greenyn also hosts health seminars, provides nutritionist consultations, and strives to enhance the physical, mental, and spiritual well-being of its employees. Additionally, it fosters a friendly workplace with employee activities, family days, employee clubs, and generous travel subsidies. The company also invests 1-3% of its annual revenue in education and training, encouraging employees to further their education and develop their careers.
Greenyn believes in aligning sustainable business practices with global trends to positively impact the environment, society, and the economy, achieving ESG goals. Since 2022, Greenyn has used the FSB's TCFD framework to assess and manage the impact of climate change, identifying related risks and opportunities. Greenyn also supports rural education, underprivileged groups, and community care programs for the elderly, regularly hosting health seminars to strengthen its commitment to social responsibility.
Achievements & Impact
Greenyn Biotechnology adopts "Innovative Research and Development," "Precision Optimization," and "Integrated Marketing" as its core strategies, actively driving growth in both the Taiwanese and global markets.
Currently, the company operates six independent factories and offices, with over 150 employees. In 2023, the company achieved a revenue of NTD 801 million, reflecting a 13.5% increase from the previous year. The company is focused on the Southeast Asian, Japanese, and Korean markets, with plans to increase the proportion of international sales to over 50% within the next 3 to 5 years.
To attract, develop, and retain a diverse workforce, Greenyn Biotechnology offers one-stop (CDMO) services for health supplements including providing clients with agency/self-developed ingredients, formulation/design services, manufacturing, packaging, and marketing services.
As a labor-intensive industry, the company strengthens talent development alongside traditional recruitment channels. With the growing need for cross-disciplinary professionals, the company collaborates with academia to expand the talent pool and enhances training for new and mid-to-senior employees. This includes technical and management training to develop the required skills. The company’s research and development team comprises 88% master's and Ph.D. degree holders and there are plans to recruit international talent to support its global expansion.
Future Direction
The company's strategy for the future focuses on research, innovation, and sustainable growth. Future product development will encompass targeting international markets, improving existing products through toxicology tests, clinical research, and international publications to support global expansion.
The company is also strengthening patents for current and future products and applying for new ones to enhance market protection. Product strategies include plant and animal extracts, as well as fermented peptides, aimed at supporting blood pressure regulation, liver protection, weight loss, and beauty, which will aid in expanding into international markets.
Greenyn Biotechnology plans to establish cross-border sales channels, having already expanded its network in Southeast Asia, Japan, and South Korea. The company is helping distributors develop local markets to boost product visibility. It is committed to obtaining regulatory certifications in key markets like Japan, Korea, and the U.S., while promoting global expansion of ingredients like Antrodia cinnamomea and Bitter Melon Peptide.
The company also participates in international exhibitions to build brand recognition and is create a big data platform to integrate product development with market planning, helping clients quickly launch new products and drive growth for their company.
Greenyn Biotechnology adopts "Innovative Research and Development," "Precision Optimization," and "Integrated Marketing" as its core strategies, actively driving growth in both the Taiwanese and global markets.
Currently, the company operates six independent factories and offices, with over 150 employees. In 2023, the company achieved a revenue of NTD 801 million, reflecting a 13.5% increase from the previous year. The company is focused on the Southeast Asian, Japanese, and Korean markets, with plans to increase the proportion of international sales to over 50% within the next 3 to 5 years.
To attract, develop, and retain a diverse workforce, Greenyn Biotechnology offers one-stop (CDMO) services for health supplements including providing clients with agency/self-developed ingredients, formulation/design services, manufacturing, packaging, and marketing services.
As a labor-intensive industry, the company strengthens talent development alongside traditional recruitment channels. With the growing need for cross-disciplinary professionals, the company collaborates with academia to expand the talent pool and enhances training for new and mid-to-senior employees. This includes technical and management training to develop the required skills. The company’s research and development team comprises 88% master's and Ph.D. degree holders and there are plans to recruit international talent to support its global expansion.
Future Direction
The company's strategy for the future focuses on research, innovation, and sustainable growth. Future product development will encompass targeting international markets, improving existing products through toxicology tests, clinical research, and international publications to support global expansion.
The company is also strengthening patents for current and future products and applying for new ones to enhance market protection. Product strategies include plant and animal extracts, as well as fermented peptides, aimed at supporting blood pressure regulation, liver protection, weight loss, and beauty, which will aid in expanding into international markets.
Greenyn Biotechnology plans to establish cross-border sales channels, having already expanded its network in Southeast Asia, Japan, and South Korea. The company is helping distributors develop local markets to boost product visibility. It is committed to obtaining regulatory certifications in key markets like Japan, Korea, and the U.S., while promoting global expansion of ingredients like Antrodia cinnamomea and Bitter Melon Peptide.
The company also participates in international exhibitions to build brand recognition and is create a big data platform to integrate product development with market planning, helping clients quickly launch new products and drive growth for their company.
CORPORATE EXCELLENCE CATEGORY
GREENYN BIOTECHNOLOGY CO., LTD.
Information about the Company
Founded in 2012, Greenyn Biotechnology Co., Ltd. is a leading international dietary supplement company. Listed on the OTD in 2023, it also serves as an exclusive distributor for foreign dietary supplement ingredients and offers ODM product development and design.
Greenyn Biotechnology focuses on developing dietary supplements with distinct Taiwanese characteristics and international competitiveness. It provides professional one-stop services, creating efficient and uniquely differentiated dietary supplement products for clients.
Greenyn Biotechnology has a proven track record of delivering thousands of customized products to hundreds of domestic and international clients over decades. Their dedicated dietitians and marketing teams collaborate with partners to ensure successful product launches.
Greenyn has obtained multiple international food quality system certifications such as FSSC 22000, ISO 22000, HACCP, HALAL, ISO/IEC 17025, GMP, and other laboratory certifications. The core values of the company coil around R&D, innovation, accurate optimization, and integrated marketing.
Greenyn leverages over two decades of marketing expertise, a strong R&D team, and collaborations with industry and academic experts to swiftly commercialize innovative products. Their commitment to excellence is reflected in their products, which feature international certifications, proven efficacy, global patents, superior specifications, and competitive pricing.
Corporate Culture & Company Activities
Greenyn Biotechnology, is recognized as a certified Healthy Workplace by the Ministry of Health and Welfare. It was also acknowledged as a "CHR Healthy Corporate Citizen" by CommonHealth Magazine in 2023.
The company values the health, safety, and dignity of all employees, while also emphasizing employee welfare and talent development. Greenyn goes beyond legal requirements, offering comprehensive health check-ups, cancer screenings and extended insurance coverage covering cancer, medical bills, and accident insurance, all fully paid by the company.
Greenyn also hosts health seminars, provides nutritionist consultations, and strives to enhance the physical, mental, and spiritual well-being of its employees. Additionally, it fosters a friendly workplace with employee activities, family days, employee clubs, and generous travel subsidies. The company also invests 1-3% of its annual revenue in education and training, encouraging employees to further their education and develop their careers.
Greenyn believes in aligning sustainable business practices with global trends to positively impact the environment, society, and the economy, achieving ESG goals. Since 2022, Greenyn has used the FSB's TCFD framework to assess and manage the impact of climate change, identifying related risks and opportunities. Greenyn also supports rural education, underprivileged groups, and community care programs for the elderly, regularly hosting health seminars to strengthen its commitment to social responsibility.
Founded in 2012, Greenyn Biotechnology Co., Ltd. is a leading international dietary supplement company. Listed on the OTD in 2023, it also serves as an exclusive distributor for foreign dietary supplement ingredients and offers ODM product development and design.
Greenyn Biotechnology focuses on developing dietary supplements with distinct Taiwanese characteristics and international competitiveness. It provides professional one-stop services, creating efficient and uniquely differentiated dietary supplement products for clients.
Greenyn Biotechnology has a proven track record of delivering thousands of customized products to hundreds of domestic and international clients over decades. Their dedicated dietitians and marketing teams collaborate with partners to ensure successful product launches.
Greenyn has obtained multiple international food quality system certifications such as FSSC 22000, ISO 22000, HACCP, HALAL, ISO/IEC 17025, GMP, and other laboratory certifications. The core values of the company coil around R&D, innovation, accurate optimization, and integrated marketing.
Greenyn leverages over two decades of marketing expertise, a strong R&D team, and collaborations with industry and academic experts to swiftly commercialize innovative products. Their commitment to excellence is reflected in their products, which feature international certifications, proven efficacy, global patents, superior specifications, and competitive pricing.
Corporate Culture & Company Activities
Greenyn Biotechnology, is recognized as a certified Healthy Workplace by the Ministry of Health and Welfare. It was also acknowledged as a "CHR Healthy Corporate Citizen" by CommonHealth Magazine in 2023.
The company values the health, safety, and dignity of all employees, while also emphasizing employee welfare and talent development. Greenyn goes beyond legal requirements, offering comprehensive health check-ups, cancer screenings and extended insurance coverage covering cancer, medical bills, and accident insurance, all fully paid by the company.
Greenyn also hosts health seminars, provides nutritionist consultations, and strives to enhance the physical, mental, and spiritual well-being of its employees. Additionally, it fosters a friendly workplace with employee activities, family days, employee clubs, and generous travel subsidies. The company also invests 1-3% of its annual revenue in education and training, encouraging employees to further their education and develop their careers.
Greenyn believes in aligning sustainable business practices with global trends to positively impact the environment, society, and the economy, achieving ESG goals. Since 2022, Greenyn has used the FSB's TCFD framework to assess and manage the impact of climate change, identifying related risks and opportunities. Greenyn also supports rural education, underprivileged groups, and community care programs for the elderly, regularly hosting health seminars to strengthen its commitment to social responsibility.
Achievements & Impact
Greenyn Biotechnology adopts "Innovative Research and Development," "Precision Optimization," and "Integrated Marketing" as its core strategies, actively driving growth in both the Taiwanese and global markets.
Currently, the company operates six independent factories and offices, with over 150 employees. In 2023, the company achieved a revenue of NTD 801 million, reflecting a 13.5% increase from the previous year. The company is focused on the Southeast Asian, Japanese, and Korean markets, with plans to increase the proportion of international sales to over 50% within the next 3 to 5 years.
To attract, develop, and retain a diverse workforce, Greenyn Biotechnology offers one-stop (CDMO) services for health supplements including providing clients with agency/self-developed ingredients, formulation/design services, manufacturing, packaging, and marketing services.
As a labor-intensive industry, the company strengthens talent development alongside traditional recruitment channels. With the growing need for cross-disciplinary professionals, the company collaborates with academia to expand the talent pool and enhances training for new and mid-to-senior employees. This includes technical and management training to develop the required skills. The company’s research and development team comprises 88% master's and Ph.D. degree holders and there are plans to recruit international talent to support its global expansion.
Future Direction
The company's strategy for the future focuses on research, innovation, and sustainable growth. Future product development will encompass targeting international markets, improving existing products through toxicology tests, clinical research, and international publications to support global expansion.
The company is also strengthening patents for current and future products and applying for new ones to enhance market protection. Product strategies include plant and animal extracts, as well as fermented peptides, aimed at supporting blood pressure regulation, liver protection, weight loss, and beauty, which will aid in expanding into international markets.
Greenyn Biotechnology plans to establish cross-border sales channels, having already expanded its network in Southeast Asia, Japan, and South Korea. The company is helping distributors develop local markets to boost product visibility. It is committed to obtaining regulatory certifications in key markets like Japan, Korea, and the U.S., while promoting global expansion of ingredients like Antrodia cinnamomea and Bitter Melon Peptide.
The company also participates in international exhibitions to build brand recognition and is create a big data platform to integrate product development with market planning, helping clients quickly launch new products and drive growth for their company.
Greenyn Biotechnology adopts "Innovative Research and Development," "Precision Optimization," and "Integrated Marketing" as its core strategies, actively driving growth in both the Taiwanese and global markets.
Currently, the company operates six independent factories and offices, with over 150 employees. In 2023, the company achieved a revenue of NTD 801 million, reflecting a 13.5% increase from the previous year. The company is focused on the Southeast Asian, Japanese, and Korean markets, with plans to increase the proportion of international sales to over 50% within the next 3 to 5 years.
To attract, develop, and retain a diverse workforce, Greenyn Biotechnology offers one-stop (CDMO) services for health supplements including providing clients with agency/self-developed ingredients, formulation/design services, manufacturing, packaging, and marketing services.
As a labor-intensive industry, the company strengthens talent development alongside traditional recruitment channels. With the growing need for cross-disciplinary professionals, the company collaborates with academia to expand the talent pool and enhances training for new and mid-to-senior employees. This includes technical and management training to develop the required skills. The company’s research and development team comprises 88% master's and Ph.D. degree holders and there are plans to recruit international talent to support its global expansion.
Future Direction
The company's strategy for the future focuses on research, innovation, and sustainable growth. Future product development will encompass targeting international markets, improving existing products through toxicology tests, clinical research, and international publications to support global expansion.
The company is also strengthening patents for current and future products and applying for new ones to enhance market protection. Product strategies include plant and animal extracts, as well as fermented peptides, aimed at supporting blood pressure regulation, liver protection, weight loss, and beauty, which will aid in expanding into international markets.
Greenyn Biotechnology plans to establish cross-border sales channels, having already expanded its network in Southeast Asia, Japan, and South Korea. The company is helping distributors develop local markets to boost product visibility. It is committed to obtaining regulatory certifications in key markets like Japan, Korea, and the U.S., while promoting global expansion of ingredients like Antrodia cinnamomea and Bitter Melon Peptide.
The company also participates in international exhibitions to build brand recognition and is create a big data platform to integrate product development with market planning, helping clients quickly launch new products and drive growth for their company.